In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens

Infection

Volumn 43, Issue 2, 2015, Pages 169-175

  Rossmann, F S ^a,b,c,d   Kropec, A ^a,d   Laverde, D ^a,d   Saaverda, F R ^a,d   Wobser, D ^a,d   Huebner, J ^a,c,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d German Center for Infection Research   (Germany)

Author keywords

Animal model; IgG; IgM; Immune globuline preparations; Nosocomial pathogens; Opsonic killing; Protective efficacy

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; PENTAGLOBULIN;

ANIMAL; BACTERIAL INFECTIONS; CROSS INFECTION; DISEASE MODEL; FEMALE; HUMAN; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; PHAGOCYTOSIS; SEPSIS;

ANIMALS; BACTERIAL INFECTIONS; CROSS INFECTION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; MICE; PHAGOCYTOSIS; SEPSIS;

EID: 84940001993     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0706-1     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention CDC. Antibiotic resistance threats in the United States 2013 Internet www.cdc.gov 2013 cited 2014 Jul 3. pp. 1–114. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/.
2. Huebner J, Arciola CR. Cave enterococcum! Int J Artif Organs. 2007;30:852–3.
3. Fabretti F, Huebner J. Implant infections due to enterococci: role of capsular polysaccharides and biofilm. Int J Artif Organs. 2005;28:1079–90.
4. Koch S, Hufnagel M, Theilacker C, Huebner J. Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine. 2004;22:822–30.
5. Talbot GH, Bradley JS, Edwards JE, Rice LB, Spellberg B. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.
6. Fox JL. Anti-infective monoclonals step in where antimicrobials fail. Nat Biotechnol. 2013;31:952–4.
7. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–6.
8. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood. 2004;104:3647–54.
9. Theilacker C, Kaczynski Z, Kropec A, Fabretti F, Sange T, Holst O, et al. Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid. Infect Immun. 2006;74:5703–12.
10. Theilacker C, Sanchez-Carballo P, Toma I, Fabretti F, Sava I, Kropec A, et al. Glycolipids are involved in biofilm accumulation and prolonged bacteraemia in Enterococcus faecalis. Mol Microbiol. 2009;71:1055–69.
11. Hufnagel M, Koch S, Creti R, Baldassarri L, Huebner J. A putative sugar-binding transcriptional regulator in a novel gene locus in Enterococcus faecalis contributes to production of biofilm and prolonged bacteremia in mice. J Infect Dis. 2004;189:420–30.
12. Theilacker C, Kropec A, Hammer F, Sava I, Wobser D, Sakinc T, et al. Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J Infect Dis. 2012;205:1076–85.
13. Theilacker C, Kaczynski Z, Kropec A, Sava I, Ye L, Bychowska A, et al. Serodiversity of opsonic antibodies against Enterococcus faecalis—glycans of the cell wall revisited. PLoS One. 2011;6:e17839.
14. Huebner J, Wang Y, Krueger WA, Madoff LC, Martirosian G, Boisot S, et al. Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun. 1999;67:1213–9.
15. Sava IG, Zhang F, Toma I, Theilacker C, Li B, Baumert TF, et al. Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J Biol Chem. 2009;284:18194–201.
16. Kropec A, Sava IG, Vonend C, Sakinc T, Grohmann E, Huebner J. Identification of SagA as a novel vaccine target for the prevention of Enterococcus faecium infections. Microbiology. 2011;157:3429–34.
17. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol. Nature Publishing Group; 2012;12:709–19.
18. Hufnagel M, Sixel K, Hammer F, Kropec A, Sava IG, Theilacker C, et al. Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations. Infection. Springer Berlin Heidelberg; 2014;42:749–55.
19. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. In: Ohlsson A, editor. Cochrane database of systematic reviews (Online). Chichester: John Wiley & Sons, Ltd; 2013;7:CD000361.
20. Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27:167–71.
21. Grönwall C, Vas J, Silverman GJ. Protective roles of natural IgM antibodies. Front Immunol. 2012;3:66.
22. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13:655–92.
23. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20:239–49.
24. Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit Care. 2002;6:357–62.
25. Barratt-Due A, Sokolov A, Gustavsen A, Hellerud BC, Egge K, Pischke SE, et al. Polyvalent immunoglobulin significantly attenuated the formation of IL-1β in Escherichia coli-induced sepsis in pigs. Immunobiology. Elsevier GmbH; 2013;218:683–9.
26. Norrby-Teglund A, Kotb M. Cytokine patterns in severe invasive group A streptococcal infections. In: Kotb M, Calandra T, editors. Cytokines and chemokines in infectious diseases handbook. Humana Press Inc; 2003. pp. 77–92.
27. Heikens E, Bonten MJM, Willems RJL. Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol. 2007;189:8233–40.
28. Pang YY, Schwartz J, Thoendel M, Ackermann LW, Horswill AR, Nauseef WM. agr-Dependent interactions of Staphylococcus aureus USA300 with human polymorphonuclear neutrophils. J Innate Immun. 2010;2:546–59.
29. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55:582–6.